Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
Conclusions: The dynamic change of CEA, CA125, CYFRA21-1, and SCC-Ag from baseline have prognostic value for late-stage NSCLC patients treated with PD-1/PD-L1 inhibitors. Decrease of associated biomarkers serum levels were associated with favorable clinical outcomes.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Adenocarcinoma | Allergy & Immunology | Cancer | Cancer & Oncology | Carcinoma | Chemistry | Chemotherapy | China Health | CT Scan | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | PET Scan | Skin Cancer | Squamous Cell Carcinoma | Study